Carbapenem-Resistant Enterobacteriaceae Infection
22
7
7
5
Key Insights
Highlights
Success Rate
63% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
13.6%
3 terminated out of 22 trials
62.5%
-24.0% vs benchmark
14%
3 trials in Phase 3/4
0%
0 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (22)
Risk Factors for Colonization or Infection With Carbapenem-Resistant Enterobacteriaceae in Children
Microbiological and Clinical Characteristics of Severe Infections Caused by Carbapenem-Resistant Enterobacterales
Different Methods of Aerosolized Polymyxin B Inhalation for Treating Carbapenem-Resistant Gram-Negative Bacterial Pneumonia.
Interventions to Decrease CRE Colonization and Transmission Between Hospitals, Households, Communities and Domesticated Animals
The Effect of Fecal Microbiota Transplantation on the Decolonization of Multidrug-resistant Organisms
Community-associated Highly-Resistant Enterobacterales
Efficacy and Safety of Colistimethate Sodium for Injection in The Treatment of Carbapenem-Resistant Enterobacteriaceae Infection
Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections
Safety and Efficacy of Fecal Microbiota Transplantation
Ceftazidime-Avibactam Use in Critically Ill Patients With Carbapenem-Resistant Enterobacteriaceae Infections
Seven Versus 14 Days of Antibiotic Therapy for Multidrug-resistant Gram-negative Bacilli Infections
EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics
Dynamics of Colonization and Infection by Multidrug-Resistant Pathogens in Immunocompromised and Critically Ill Patients
Precise Treatment of Ceftazidime-Avibactam in Patients With CRO Infections Under the Guidance of TDM and PPK Model
Fecal Microbiota Transplantation for Decolonization of Carbapenem-resistant Enterobacteriaceae
Drug Resistance Mechanism of Enterobacteriaceae and Its Strategies
Fecal Microbiota Transplantation for Carbapenem-resistant Enterobacteriaceae
Fecal Microbiota Transplantation for Carbapenem Resistant Enterobacteriaceae
Best Available Therapy With or Without Meropenem for Bloodstream Infections by Enterobacterales With High Level of Resistance to Carbapenems
Impact of Ceftazidime / Avibactam Treatment vs Better Available Therapy on Mortality of Patients With Infections Caused by Carbapenem-resistant Enterobacteria